- Home
- REGN vs PLD Comparison
REGN vs PLD Comparison
Compare REGN & PLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- PLD
- Stock Information
- Founded
- REGN 1988
- PLD 1983
- Country
- REGN United States
- PLD United States
- Employees
- REGN N/A
- PLD N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- PLD Real Estate Investment Trusts
- Sector
- REGN Health Care
- PLD Real Estate
- Exchange
- REGN Nasdaq
- PLD Nasdaq
- Market Cap
- REGN 110.0B
- PLD 103.1B
- IPO Year
- REGN 1991
- PLD 1994
- Fundamental
- Price
- REGN $681.58
- PLD $109.45
- Analyst Decision
- REGN Buy
- PLD Buy
- Analyst Count
- REGN 25
- PLD 17
- Target Price
- REGN $1,024.28
- PLD $129.41
- AVG Volume (30 Days)
- REGN 857.0K
- PLD 4.9M
- Earning Date
- REGN 02-04-2025
- PLD 01-21-2025
- Dividend Yield
- REGN N/A
- PLD 3.51%
- EPS Growth
- REGN 15.31
- PLD 2.06
- EPS
- REGN 40.43
- PLD 3.31
- Revenue
- REGN $13,847,100,000.00
- PLD $8,239,209,999.00
- Revenue This Year
- REGN $10.24
- PLD N/A
- Revenue Next Year
- REGN $4.30
- PLD $7.44
- P/E Ratio
- REGN $16.86
- PLD $33.07
- Revenue Growth
- REGN 5.72
- PLD 0.81
- 52 Week Low
- REGN $666.25
- PLD $100.82
- 52 Week High
- REGN $1,211.20
- PLD $135.76
- Technical
- Relative Strength Index (RSI)
- REGN 36.27
- PLD 53.33
- Support Level
- REGN $666.25
- PLD $103.23
- Resistance Level
- REGN $743.28
- PLD $112.00
- Average True Range (ATR)
- REGN 19.76
- PLD 2.48
- MACD
- REGN 0.45
- PLD 0.91
- Stochastic Oscillator
- REGN 19.90
- PLD 70.92
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About PLD Prologis Inc.
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.2 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.